Cyclic adenosine 3',5'-monophosphate-binding proteins in human ovarian cancer: correlations with clinicopathological features.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Clinical Cancer Research

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 9816107
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumour cyclic AMP binding proteins: an independent prognostic factor for disease recurrence and survival in breast cancer

  2004cited by this paper
• Phase I clinical study with 8-chloro-cAMP and evaluation of immunological effects in cancer patients

  1995cited by this paper
• Growth inhibition by 8-chloro cyclic AMP of human HT29 colorectal and ZR-75-1 breast carcinoma xenografts is associated with selective modulation of protein kinase A isoenzymes.

  1995cited by this paper
• Cyclic adenosine 3',5'-monophosphate-binding proteins in human ovarian cancers.

  1994cited by this paper
• Protein kinase A (PK-A) regulatory subunit expression in colorectal cancer and related mucosa.

  1994cited by this paper
• An antisense oligodeoxynucleotide that depletes RI alpha subunit of cyclic AMP-dependent protein kinase induces growth inhibition in human cancer cells.

  1993cited by this paper
• Survival determinants in patients with advanced ovarian cancer.

  1993cited by this paper
• Differentiation therapy of cancer targeting the ri-alpha regulatory subunit of cAMP-dependent protein-kinase (review).

  1993cited by this paper
• Role of site-selective cAMP analogs in the control and reversal of malignancy.

  1991cited by this paper
• Cyclic AMP binding proteins and prognosis in breast cancer.

  1990cited by this paper
• Changes in diacylglycerol and membrane associated protein kinase C activity reflect the growth status of xenografted human mammary carcinoma treated with 8-Cl-cAMP.

  1990cited by this paper
• Site-selective cAMP analogs at micromolar concentrations induce growth arrest and differentiation of acute promyelocytic, chronic myelocytic, and acute lymphocytic human leukemia cell lines.

  1988cited by this paper
• Selective modulation of protein kinase isozymes by the site-selective analog 8-chloroadenosine 3',5'-cyclic monophosphate provides a biological means for control of human colon cancer cell growth.

  1988influential reference
• Synergistic inhibition of growth of breast and colon human cancer cell lines by site-selective cyclic AMP analogues.

  1988cited by this paper
• Type I and II cyclic adenosine 3':5'-monophosphate-dependent protein kinase in human gastric mucosa and carcinomas.

  1985cited by this paper
• Protein kinases in human renal cell carcinoma and renal cortex. A comparison of isozyme distribution and of responsiveness to adenosine 3':5'-cyclic monophosphate.

  1978cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper
• Photoaffinity labeling of a protein kinase from bovine brain with 8-azidoadenosine 3',5'-monophosphate.

  1975cited by this paper
• Purification and properties of rabbit skeletal muscle adenosine 3',5'-monophosphate-dependent protein kinases.

  1971cited by this paper
• An adenosine 3',5'-monophosphate-dependant protein kinase from rabbit skeletal muscle.

  1968cited by this paper
• THE ATTRACTIONS OF PROTEINS FOR SMALL MOLECULES AND IONS

  1949cited by this paper

• The Role of Human Chorionic Gonadotropin Beta (hCGβ) in HPV-Positive and HPV-Negative Oropharyngeal Squamous Cell Carcinoma

  2022cites this paper
• Causal effect of sex hormone-binding globulin and testosterone on coronary heart disease: A multivariable and network Mendelian randomization analysis.

  2021cites this paper
• N-arylpiperazine-containing compound (C2): An enhancer of sunitinib in the treatment of pancreatic cancer, involving D1DR activation.

  2019cites this paper
• Sex hormone binding globulin and risk of breast cancer: a Mendelian randomization study.

  2019cites this paper
• QUANTUM ANALYSIS OF THE CYCLIC ADENOSINE MONOPHOSPHATE (AMPc) AND GUANOSINE MONOPHOSPHATE CYCLIC (GMPc) IN NEUROTRANSMITTERS

  2018cites this paper
• Loss of phosphodiesterase 4D mediates acquired triapine resistance via Epac-Rap1-Integrin signaling

  2016cites this paper
• MiR-141 inhibits colorectal cancer cell proliferation and invasion by targeting PRKAR 1 A

  2016cites this paper
• Bioinformatic analysis of miRNA expression patterns in TFF2 knock-out mice.

  2014cites this paper
• Suppression of GNAI2 message in ovarian cancer

  2014cites this paper
• Dopamine receptor subtypes functional regulation in insulin induced hypoglycemic neonatal rats: effect of glucose, bacopa monnieri and bacoside a resuscitation

  2014cites this paper
• Comparison of two type IV hyperthermophilic adenylyl cyclases characterizations from the archaeon Pyrococcus furiosus

  2013cites this paper
• A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers.

  2012cites this paper
• Suppression of PRKAR1A expression enhances anti-proliferative and apoptotic effects of protein kinase inhibitors and chemotherapeutic drugs on cholangiocarcinoma cells.

  2012cites this paper
• Development of luminescent sensing systems with clinical applications

  2011cites this paper
• Protein Kinase A Activation Confers Resistance to Trastuzumab in Human Breast Cancer Cell Lines

  2009cites this paper
• Androgen dependent regulation of protein kinase A subunits in prostate cancer cells.

  2007cites this paper
• Altered gene expression in Opisthorchis viverrini‐associated cholangiocarcinoma in hamster model

  2006cites this paper
• Inherited disposition to cardiac myxoma development

  2006cites this paper
• Antisense Protein Kinase A-RIα Restores Normal Signal Transduction Signatures to Inhibit Tumor Growth

  2004cites this paper
• Antisense protein kinase A RIalpha acts synergistically with hydroxycamptothecin to inhibit growth and induce apoptosis in human cancer cells: molecular basis for combinatorial therapy.

  2003cites this paper
• Antisense DNAs as targeted genetic medicine to treat cancer

  2003cites this paper
• cAMP signaling in cancer genesis and treatment.

  2003cites this paper
• Antisense Oligonucleotides Targeting RIα Subunit of Protein Kinase A

  2003cites this paper
• Gene expression profiling during all-trans retinoic acid-induced cell differentiation of acute promyelocytic leukemia cells.

  2003cites this paper
• Genome-wide expression profiling of 8-chloroadenosine- and 8-chloro-cAMP-treated human neuroblastoma cells using radioactive human cDNA microarray

  2002cites this paper
• Protein kinase A RIalpha antisense inhibition of PC3M prostate cancer cell growth: Bcl-2 hyperphosphorylation, Bax up-regulation, and Bad-hypophosphorylation.

  2002cites this paper
• Antisense DNAs as multisite genomic modulators identified by DNA microarray

  2001cites this paper
• Antisense anticancer oligonucleotide therapeutics.

  2001cites this paper
• Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production.

  2000cites this paper
• A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors.

  2000cites this paper
• Oligonucleotide Sequence-Specific Inhibition of Gene Expression, Tumor Growth Inhibition, and Modulation of cAMP Signaling by an RNA-DNA Hybrid Antisense Targeted to Protein Kinase A RIα Subunit

  2000cites this paper
• Targeting of epidermal growth factor receptor and protein kinase A: molecular basis and therapeutic applications.

  2000cites this paper
• Antisense and therapeutic oligonucleotides: toward a gene-targeting cancer clinic

  2000cites this paper
• Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration.

  1999cites this paper
• Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth.

  1999cites this paper
• Increased expression of the RIα subunit of the cAMP-dependent protein kinase A is associated with advanced stage ovarian cancer

  1999influential citation
• Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A.

  1997cites this paper
• Review Targeting of Epidermal Growth Factor Receptor and Protein Kinase A: Molecular Basis and Therapeutic Applications

  year unknowncites this paper